Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. QSI
QSI logo

QSI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.060
Open
1.030
VWAP
1.01
Vol
6.82M
Mkt Cap
231.51M
Low
0.981
Amount
6.90M
EV/EBITDA(TTM)
--
Total Shares
216.37M
EV
68.61M
EV/OCF(TTM)
--
P/S(TTM)
86.84
Quantum-SI Incorporated is a life sciences company. The Company has designed and developed a hardware, consumable and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins. Its launched product consists of Platinum, the Platinum Analysis Software and consumables. Its flagship protein sequencing instrument, Platinum, is designed to make the power of single-molecule detection and NGPS accessible. Platinum is designed to provide a streamlined workflow compared to legacy MS workflows. Platinum uses its proprietary semiconductor chip that leverages time-domain sequencing with an initial focus on NGPS for an unbiased view of the proteome.
Show More

Events Timeline

(ET)
2026-04-14
08:40:00
Quantum-Si Releases New Study on Human Cohesin Function in Yeast
select
2026-04-08 (ET)
2026-04-08
09:20:00
Quantum-Si Completes Sequencing on Proteus Prototype System
select
2026-03-04 (ET)
2026-03-04
15:50:00
IonQ Q4 Exceeds Expectations with $61.9 Million Revenue
select
2026-03-03 (ET)
2026-03-03
16:20:00
Company Reports Q4 Revenue of $451K, Below Expectations
select
2025-12-05 (ET)
2025-12-05
08:50:00
Significant Increases in Borrow Rates for Liquid Option Names
select

News

Newsfilter
9.5
04-16Newsfilter
Quantum-Si to Report Q1 2026 Financial Results on May 7
  • Earnings Report Schedule: Quantum-Si will announce its Q1 2026 financial results on May 7, 2026, reflecting the company's commitment to transparency and investor communication, which is expected to attract more investor interest.
  • Executive Conference Call: CEO Jeff Hawkins and CFO Jeff Keyes will host a conference call at 4:30 PM ET on the same day to discuss financial results and provide a business update, aiming to bolster investor confidence in the company's future growth.
  • Webcast Participation: Investors can join the live webcast of the conference call via the Investors section of the Quantum-Si website, enhancing interaction between the company and its investors and facilitating timely information dissemination.
  • Platform Technology Advantage: Quantum-Si's platform simplifies protein analysis through single-molecule detection, improving research efficiency and is expected to drive significant breakthroughs in the proteomics field, thereby strengthening the company's competitive position in the market.
Newsfilter
8.5
04-15Newsfilter
Quantum-Si Showcases New Technology at AACR Conference
  • Customer Poster Presentation: Quantum-Si will present two customer posters at the AACR annual meeting from April 17-22, 2026, focusing on DNA repair inhibitors and high-resolution detection of post-translational modifications, showcasing the application potential of its single-molecule protein sequencing technology.
  • Technological Innovation: The first poster, led by Dr. Nigel O'Neil, introduces a method combining deep mutational scanning with next-generation protein sequencing aimed at developing therapeutics targeting DNA repair enzymes, highlighting the technology's significance in cancer treatment.
  • Application Prospects: The second poster, led by Dr. Gloria Sheynkman, demonstrates the ability to detect multiple post-translational modifications using Quantum-Si's single-molecule protein sequencing technology, indicating the technology's broad application potential in biomarker studies.
  • Market Strategy: CEO Jeff Hawkins stated that the company invested significant effort in 2025 to build a pipeline of studies, aiming to enhance market awareness through customer data presentations and lay the groundwork for the upcoming launch of Proteus™.
Newsfilter
3.5
04-14Newsfilter
Quantum-Si Unveils New Research on Human Cohesin Complexes
  • Research Publication: Quantum-Si announced the publication of a collaborative study with the University of British Columbia and B.C. Cancer Research Institute on bioRxiv, revealing that human cohesins form complexes in yeast cells, which may impact cancer drug development.
  • Technological Value: The study utilized Quantum-Si's single-molecule protein sequencing technology to provide direct, unbiased data demonstrating the assembly of human and yeast cohesin proteins into the same complexes, highlighting the technology's significance in mechanistic biology research.
  • Impact on Cancer Research: The dysfunction of cohesins is linked to genomic instability in tumors, and the findings offer new avenues for targeting cancer cells, potentially driving the development of novel anti-cancer therapies.
  • Strategic Positioning: Quantum-Si's platform aims to enhance research efficiency by simplifying and accelerating protein analysis workflows, thereby strengthening its market position in the proteomics field and facilitating future commercialization efforts.
Newsfilter
5.0
04-10Newsfilter
Quantum-Si Grants 61,439 RSUs to New Employees Under 2023 Inducement Plan
  • Employee Incentive Plan: Quantum-Si has granted 61,439 restricted stock units (RSUs) to new employees under the 2023 Inducement Equity Incentive Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in protein analysis.
  • Vesting Conditions: The RSUs will vest 25% on June 20, 2027, with the remainder vesting in 12 equal quarterly installments, ensuring continued employee contributions during their tenure at Quantum-Si.
  • Regulatory Compliance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring Quantum-Si adheres to relevant regulations while attracting new employees, thereby enhancing corporate governance transparency.
  • Technological Innovation Context: Quantum-Si is transforming proteomics with its benchtop platform, making single-molecule protein analysis simpler and more efficient, thus driving scientific advancements and strengthening the company's market position.
Newsfilter
3.5
04-08Newsfilter
Quantum-Si's Proteus Prototype Surpasses Platinum Performance
  • Successful Sample Sequencing: Quantum-Si has successfully completed the sequencing of multiple samples on its Proteus prototype system, demonstrating that it exceeds Platinum Pro performance across all relevant metrics, marking a significant milestone in the development of this new platform.
  • Significant Technical Advantages: The Proteus prototype system shows substantial improvements in amino acid coverage, read lengths, peptide identification, and sequencing output, even when normalized for the difference in nanowell counts compared to the Platinum Pro chip, highlighting its superior performance.
  • Strong Customer Demand: Several customers have expressed interest in providing samples for sequencing on the Proteus prototype, and Quantum-Si is closely collaborating with manufacturing partners to increase the delivery rate of integrated Proteus systems to meet internal R&D demands and offer market sample testing capabilities.
  • Optimistic Future Outlook: Quantum-Si expects sequencing performance to continue improving as the Proteus system is further optimized, with plans to provide more updates on this program during the next earnings call, reflecting the company's confidence in future developments.
Newsfilter
8.5
04-06Newsfilter
Quantum-Si Launches Multi-City Roadshow for Proteus Awareness
  • Roadshow Launch: Quantum-Si has announced the start of a multi-city roadshow aimed at increasing market awareness of its Proteus platform and protein sequencing applications, with the first event scheduled for April 7, 2026, in Seattle, followed by stops in Washington D.C. and Houston, which is expected to significantly expand its potential customer base.
  • Customer Engagement: The roadshow will feature presentations from existing customers showcasing applications of protein sequencing using the company's first-generation Platinum® Pro instrument, which not only helps build customer trust but also creates strong market demand for the upcoming Proteus platform.
  • Market Education: Through this roadshow, Quantum-Si aims to accelerate market education and enhance awareness of Proteus, which is expected to exceed the capabilities of Platinum Pro, thereby positioning the company more favorably in the competitive protein analysis market.
  • Strategic Importance: CEO Jeff Hawkins stated that this roadshow is a crucial part of the company's pre-launch strategy, designed to rapidly build a funnel of prospective customers through the effectiveness of its direct sales team, laying the groundwork for the commercialization of Proteus.
Wall Street analysts forecast QSI stock price to rise
3 Analyst Rating
Wall Street analysts forecast QSI stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
1.50
Averages
2.67
High
4.00
Current: 0.000
sliders
Low
1.50
Averages
2.67
High
4.00
Canaccord
Kyle Mikson
Hold
downgrade
$1
AI Analysis
2026-03-05
Reason
Canaccord
Kyle Mikson
Price Target
$1
AI Analysis
2026-03-05
downgrade
Hold
Reason
Canaccord analyst Kyle Mikson lowered the firm's price target on Quantum-Si to $1 from $1.50 and keeps a Hold rating on the shares. The firm said 4Q25 results below our estimates and FactSet consensus. They estimate low-single-digit Platinum instrument sales in the quarter, with gross margin of approximately 27%. Importantly, QSI has largely shifted its focus to the launch of the Proteus platform, framing 2026 as a "transition year."
Canaccord
Hold
downgrade
$2
2025-12-22
Reason
Canaccord
Price Target
$2
2025-12-22
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Quantum-Si to $1.50 from $2 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for QSI
Unlock Now

Valuation Metrics

The current forward P/E ratio for Quantum-Si Inc (QSI.O) is 0.00, compared to its 5-year average forward P/E of -4.25. For a more detailed relative valuation and DCF analysis to assess Quantum-Si Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.25
Current PE
0.00
Overvalued PE
-0.72
Undervalued PE
-7.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.49
Current EV/EBITDA
-0.47
Overvalued EV/EBITDA
2.39
Undervalued EV/EBITDA
-5.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
75.52
Current PS
23.42
Overvalued PS
166.97
Undervalued PS
-15.94

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stocks to buy from 50 cents to 1 $
Intellectia · 277 candidates
Price: $0.50 - $1.00
Ticker
Name
Market Cap$
top bottom
ALIT logo
ALIT
Alight Inc
485.11M
DVLT logo
DVLT
Datavault AI Inc
400.52M
UP logo
UP
Wheels Up Experience Inc
389.82M
LAB logo
LAB
Standard BioTools Inc
357.84M
BYND logo
BYND
Beyond Meat Inc
331.79M
GETY logo
GETY
Getty Images Holdings Inc
321.38M
what should I buy under 1.00 a share?
Intellectia · 344 candidates
Price: $0.10 - $1.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
ALIT logo
ALIT
Alight Inc
507.72M
UP logo
UP
Wheels Up Experience Inc
406.86M
LAB logo
LAB
Standard BioTools Inc
392.26M
GETY logo
GETY
Getty Images Holdings Inc
360.43M
BYND logo
BYND
Beyond Meat Inc
352.61M
CAN logo
CAN
Canaan Inc
345.29M

Whales Holding QSI

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Quantum-Si Inc (QSI) stock price today?

The current price of QSI is 0.99735 USD — it has decreased -6.82

What is Quantum-Si Inc (QSI)'s business?

Quantum-SI Incorporated is a life sciences company. The Company has designed and developed a hardware, consumable and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins. Its launched product consists of Platinum, the Platinum Analysis Software and consumables. Its flagship protein sequencing instrument, Platinum, is designed to make the power of single-molecule detection and NGPS accessible. Platinum is designed to provide a streamlined workflow compared to legacy MS workflows. Platinum uses its proprietary semiconductor chip that leverages time-domain sequencing with an initial focus on NGPS for an unbiased view of the proteome.

What is the price predicton of QSI Stock?

Wall Street analysts forecast QSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QSI is2.67 USD with a low forecast of 1.50 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Quantum-Si Inc (QSI)'s revenue for the last quarter?

Quantum-Si Inc revenue for the last quarter amounts to 451.00K USD, decreased -62.16

What is Quantum-Si Inc (QSI)'s earnings per share (EPS) for the last quarter?

Quantum-Si Inc. EPS for the last quarter amounts to -0.08 USD, decreased -65.22

How many employees does Quantum-Si Inc (QSI). have?

Quantum-Si Inc (QSI) has 145 emplpoyees as of April 20 2026.

What is Quantum-Si Inc (QSI) market cap?

Today QSI has the market capitalization of 231.51M USD.